$ News

Virpax Pharmaceuticals Announces Reverse Stock Split

Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND

Virpax Looking to Use MET to Develop Intranasal COVID Vaccine

Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS

Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology

Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate

Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study

Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference

Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering

Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants

Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™

Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering

Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Warning: VRPX is at high risk of performing badly

Maxim gets more bearish on Virpax Pharmaceuticals, downgrades shares

Virpax Pharmaceuticals Faces Nasdaq Delisting Risk

Virpax Pharmaceuticals Announces Key Management Changes